Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.56 EUR | -4.21% | -1.89% | +102.22% |
May. 15 | Medincell: share price falls after disappointing clinical study | CF |
May. 14 | Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+102.22% | 473M | - | ||
+31.37% | 588B | B | ||
-2.60% | 364B | C+ | ||
+20.83% | 326B | B- | ||
+5.69% | 285B | C+ | ||
+14.83% | 239B | B+ | ||
+9.93% | 210B | B- | ||
-6.95% | 200B | A+ | ||
+10.77% | 167B | C+ | ||
+0.10% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MEDCL Stock
- Ratings MedinCell S.A.